Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis

Background Lysophosphatidic acid (LPA) governs a number of physiologic and pathophysiological processes. Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer. However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer. Methodology and Principal Findings In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment. The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma. Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis. Patients with LPA-signature-positive ovarian tumors have reduced disease-specific and progression-free survival times. They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased. Among the 39-gene signature, a group of seven genes associated with cell adhesion recapitulated the results. Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma. Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration. Conclusions The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.

[1]  G. Mills,et al.  Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression , 2007, Expert Reviews in Molecular Medicine.

[2]  G. Mills,et al.  The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. , 2003, Cancer research.

[3]  J. Schwarzbauer,et al.  Ligand density and integrin repertoire regulate cellular response to LPA. , 2006, Matrix biology : journal of the International Society for Matrix Biology.

[4]  Elisa Rossi,et al.  Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. , 2007, American journal of obstetrics and gynecology.

[5]  Gordon B Mills,et al.  Lysophosphatidic acid is a bioactive mediator in ovarian cancer. , 2002, Biochimica et biophysica acta.

[6]  Yiling Lu,et al.  Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. , 2008, Journal of the National Cancer Institute.

[7]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[8]  Yiling Lu,et al.  Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. , 2008, Advances in experimental medicine and biology.

[9]  D. Montell,et al.  Ovarian Cancer Metastasis: Integrating insights from disparate model organisms , 2005, Nature Reviews Cancer.

[10]  Anne-Marie Mes-Masson,et al.  Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling , 2005, Oncogene.

[11]  N. Auersperg,et al.  E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[13]  Ben Davidson,et al.  Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. , 2008, Human pathology.

[14]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[15]  G. Mills,et al.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  G. Mills,et al.  Lysophosphatidic acid production and action: Validated targets in cancer? , 2004, Journal of cellular biochemistry.

[17]  R. Kurman,et al.  Pathology of ovarian carcinoma. , 2003, Hematology/oncology clinics of North America.

[18]  B. Seed,et al.  A PCR primer bank for quantitative gene expression analysis. , 2003, Nucleic acids research.

[19]  G. Mills,et al.  Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. , 2006, Cancer research.

[20]  P. Disaia,et al.  Clinical Gynecologic Oncology , 1981 .

[21]  Yan Xu,et al.  Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. , 2001, Gynecologic oncology.

[22]  S. Rodenhuis,et al.  Malignant effusions contain lysophosphatidic acid (LPA)-like activity. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[24]  G. Mills,et al.  Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Yan Xu,et al.  Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. , 2001, Analytical biochemistry.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  G. Mills,et al.  Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. , 2008, Biochimica et biophysica acta.

[28]  F. Hofmann,et al.  Lysophosphatidic acid-mediated signal-transduction pathways involved in the induction of the early-response genes prostaglandin G/H synthase-2 and Egr-1: a critical role for the mitogen-activated protein kinase p38 and for Rho proteins. , 1998, The Biochemical journal.

[29]  N. Udvarhelyi,et al.  Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. , 2006, Gynecologic oncology.

[30]  P. Morin,et al.  Claudin proteins in human cancer: promising new targets for diagnosis and therapy. , 2005, Cancer research.

[31]  R. Getzenberg,et al.  Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. , 2004, Endocrinology.

[32]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[33]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[34]  D. Mosher,et al.  Lysophosphatidic acid enhances fibronectin binding to adherent cells. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[35]  Kathleen R. Cho,et al.  Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. , 2006, Cancer research.

[36]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[37]  Y. Xu,et al.  Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. , 1998, Gynecologic oncology.

[38]  Russ B. Altman,et al.  Missing value estimation methods for DNA microarrays , 2001, Bioinform..

[39]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  György Horvath,et al.  Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. , 2006, European journal of cancer.

[41]  Gordon B Mills,et al.  Lysophosphatidic acid (LPA)‐induced vasodilator‐stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC‐3 prostate cancer cells , 2008, Molecular oncology.

[42]  M. Washington,et al.  Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. , 2005, The Journal of clinical investigation.

[43]  G. Mills,et al.  Carba Analogs of Cyclic Phosphatidic Acid Are Selective Inhibitors of Autotaxin and Cancer Cell Invasion and Metastasis* , 2006, Journal of Biological Chemistry.

[44]  G. Mills,et al.  Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer , 2006 .

[45]  Wing H Wong,et al.  Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.

[46]  I. Shih,et al.  The diagnostic role of claudins in serous effusions. , 2007, American journal of clinical pathology.

[47]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.